摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methyl-1-(β-D-erythro-pentofuranosyl)-1H-benzimidazole | 651046-73-0

中文名称
——
中文别名
——
英文名称
4-methyl-1-(β-D-erythro-pentofuranosyl)-1H-benzimidazole
英文别名
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(4-methylbenzimidazol-1-yl)oxolane-3,4-diol
4-methyl-1-(β-D-erythro-pentofuranosyl)-1H-benzimidazole化学式
CAS
651046-73-0
化学式
C13H16N2O4
mdl
——
分子量
264.281
InChiKey
PPRLTHYXZHHGEZ-OJAKKHQRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    87.7
  • 氢给体数:
    3
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    4-methyl-1-(β-D-erythro-pentofuranosyl)-1H-benzimidazole4-甲氧基三苯基氯甲烷吡啶 作用下, 反应 4.0h, 以52%的产率得到4-methyl-1-[5'-O-(4-monomethoxytrityl)-β-D-erythro-pentofuranosyl]-1H-benzimidazole
    参考文献:
    名称:
    Biomimetic self-condensation of malonates mediated by nucleosides
    摘要:
    Nucleoside mediated Claisen condensation of malonates has been achieved under biomimetic weak acid conditions, pH 3 or 4, 0.15M NaCl, and 0.125M Mg2+. The result illustrates the catalyzing property of end-nucleosides of t-RNA in the RNA world. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2007.09.036
  • 作为产物:
    描述:
    1-乙酰氧基-2,3,5-三苯甲酰氧基-1-beta-D-呋喃核糖7 - 甲基-1H -苯并[D]咪唑四氯化锡 作用下, 以 1,2-二氯乙烷甲醇 为溶剂, 反应 5.0h, 以55%的产率得到4-methyl-1-(β-D-erythro-pentofuranosyl)-1H-benzimidazole
    参考文献:
    名称:
    Regioselective Synthesis of 2-Substituted-4-Methylbenzimidazole Nucleosides
    摘要:
    一系列2-取代-4-甲基苯并咪唑核苷被高立体选择性和区域选择性地合成,并讨论了其意外的区域选择性。这些化合物可以工业规模制备,因为它们以良好的产率获得,无需色谱分离。
    DOI:
    10.1055/s-2005-865227
点击查看最新优质反应信息

文献信息

  • Steric Effects in RNA Interference: Probing the Influence of Nucleobase Size and Shape
    作者:Alvaro Somoza、Adam P. Silverman、Rand M. Miller、Jijumon Chelliserrykattil、Eric T. Kool
    DOI:10.1002/chem.200800837
    日期:2008.9.8
    Sequence-selectivity studies were carried out at this position with mutated target mRNAs and nucleobase analogues with varied size (2,4-difluoro- and 2,4-dichlorobenzene) and different shape (2,3-dichlorobenzene, 4-methylbenzimidazole). The results point out the importance of nucleobase shape and steric effects in RNA interference.
    具有不同大小和形状的非极性核苷已被用于研究氢键稳定和空间效应对RNA干扰的影响。siRNA导链的尿嘧啶腺嘌呤残基已被尿嘧啶腺嘌呤的非极性等位基因以及空间变体所取代。针对海肾荧光素酶mRNA的RNAi实验表明,siRNA热稳定性与基因抑制密切相关。有趣的是,在引导链上第7位修饰的siRNA没有遵循这种相关性,尽管具有较低的热稳定性,但仍具有大量的RNAi活性。在此位置进行了具有可变大小(2,4-二和2,4-二氯苯)和不同形状(2,3-二氯苯,4-甲基苯并咪唑)的突变靶mRNA和核碱基类似物的序列选择性研究。
查看更多

同类化合物

直链-苯并腺苷二磷酸酯 [(2R,3R,4R,5R)-2-(5,6-二氯苯并咪唑-1-基)-4-羟基-5-(羟基甲基)四氢呋喃-3-基]磷酸二氢酯 BENZIMIDAVIR苯并咪唑核苷 8-氨基-3-beta-D-呋喃核糖基咪唑并[4,5-g]喹唑啉 5,6-二甲基-1-(5-O-膦酰-alpha-D-呋喃核糖基)-1H-苯并咪唑 5,6-二氯-1-β-D-呋喃核糖基苯并咪唑 2-氯-5,6-二甲基-1-beta-D-呋喃核糖基苯并咪唑 2,5-哌嗪二酮,3-甲基-6-(2-甲基丙基)-,反-(9CI) 1,3-二去氮杂腺苷 (2S,3R,4S,5R)-2-(5,6-二甲基苯并咪唑-1-基)-5-(羟基甲基)四氢呋喃-3,4-二醇 2-amino-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole 2,5,6-trichloro-1-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyl)benzimidazole 1-(2',3',5'-tri-O-acetyl-α-D-lyxofuranosyl)-2,5,6-trichlorobenzimidazole Acetic acid (2R,3R,4R,5S)-4-acetoxy-5-acetoxymethyl-2-(2-bromo-5,6-dichloro-benzoimidazol-1-yl)-tetrahydro-furan-3-yl ester α-Ribazol-3'(2')-phosphorsaeureester 1-(2,3,5-tri-O-acetyl-α-L-lyxofuranosyl)-2,5,6-trichlorobenzimidazole 2'-Benzoyl-1-β-D-ribofuranosylbenzimidazol (1Ξ)-1-(5,6-dimethyl-benzimidazol-1-yl)-1,4-anhydro-L-arabitol 1-(6-acetylamino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-α-D-1-deoxy-ribofuranose 2-azido-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole 3'-Benzoyl-1-β-D-ribofuranosylbenzimidazol tri-O-acetyl-1-(8-methylsulfanyl-imidazo[4,5-g]quinazolin-1-yl)-β-D-1-deoxy-ribofuranose 3-aminopropyl-2'-(α-ribazolyl)-diphosphate 1-(6-acetylamino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-β-D-1-deoxy-ribofuranose 1-(6-amino-4-methylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-β-D-1-deoxy-ribofuranose 2-iodo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole Formamidoribosid 2-bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-L-ribofuranosyl)benzimidazole Formamidoribosid 5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole-2-thione 1-(tri-O-benzoyl-β-D-ribofuranosyl)-1,3-dihydro-benzoimidazole-2-thione 5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole bis(triethylammonium) salt 5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole triethylammonium salt tri-O-benzoyl-1-(2-methylsulfanyl-benzoimidazol-1-yl)-β-D-1-deoxy-ribofuranose 2-Allylthio-1-(β-D-ribofuranosyl)benzimidazol 1-benzoimidazol-1-yl-tri-O-benzoyl-α-D-1-deoxy-ribofuranose Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-(4,6-dichloro-2-thioxo-2,3-dihydro-benzoimidazol-1-yl)-tetrahydro-furan-3-yl ester 2-Chloro-6-bromo-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 6-amino-1-(tri-O-benzoyl-β-D-ribofuranosyl)-1,5-dihydro-imidazo[4,5-c]pyridine-4-thione Bis-5',5'- 1-(6-amino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-β-D-1-deoxy-ribofuranose (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(5,6-dimethoxy-1H-benzo[d]imidazol-1-yl)tetrahydrofuran-3,4-diyl diacetate 2-azido-4,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 2-bromo-4,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 2,4,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole 1-(2,3,5-Tri-O-acetyl-α-D-ribofuranosyl)-5,6-dimethyl-benzimidazol od. α-Ribazol-triacetat 2,4,6-trichloro-1-(2,3,5-tri-O-acetyl-α-D-ribofuranosyl)benzimidazole 2-bromo-6-trifluoromethyl-1-(5-deoxy-beta-D-ribofuranosyl)-1H-benzimidazole